SBTX vs. ADCT, FBLG, URGN, AMRN, ANNX, MREO, PGEN, VTYX, ORGO, and NATR
Should you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include ADC Therapeutics (ADCT), FibroBiologics (FBLG), UroGen Pharma (URGN), Amarin (AMRN), Annexon (ANNX), Mereo BioPharma Group (MREO), Precigen (PGEN), Ventyx Biosciences (VTYX), Organogenesis (ORGO), and Nature's Sunshine Products (NATR). These companies are all part of the "pharmaceutical preparations" industry.
ADC Therapeutics (NYSE:ADCT) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are owned by institutional investors. 35.4% of ADC Therapeutics shares are owned by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
ADC Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
ADC Therapeutics presently has a consensus price target of $6.33, suggesting a potential upside of 50.79%. Given Silverback Therapeutics' higher probable upside, research analysts plainly believe ADC Therapeutics is more favorable than Silverback Therapeutics.
ADC Therapeutics received 29 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 62.67% of users gave ADC Therapeutics an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote.
In the previous week, ADC Therapeutics had 1 more articles in the media than Silverback Therapeutics. MarketBeat recorded 1 mentions for ADC Therapeutics and 0 mentions for Silverback Therapeutics. ADC Therapeutics' average media sentiment score of 0.00 beat Silverback Therapeutics' score of -1.00 indicating that Silverback Therapeutics is being referred to more favorably in the news media.
Silverback Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
Silverback Therapeutics has a net margin of 0.00% compared to Silverback Therapeutics' net margin of -344.15%. ADC Therapeutics' return on equity of -29.62% beat Silverback Therapeutics' return on equity.
Summary
ADC Therapeutics beats Silverback Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Silverback Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Silverback Therapeutics Competitors List
Related Companies and Tools